PPAT

Across TCGA pan-cancer cohorts, PPAT Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PPAT data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PPAT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPAT expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LUAD, UCEC, and STAD are the cancer types where PPAT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.194	0.813	<.001	24	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
STAD	DFS	Median	All	1.000	0.391	.044	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PPAT–LUAD (OS)

Open the LUAD breakdown →